FEV collaborates with Microsoft on efficient AI model approach for incar applications built on NVIDIA
more
Stories from Aachen
- Language:
- Media:
- Period:
- Period:Total
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy
Aachen (ots) - Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid ...
moreGrünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist
Aachen (ots) - - The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. - In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. - A Phase II trial will commence later this year. Grünenthal announced today that the ...
morePLAN-B NET ZERO integrates measurable impact into electricity tariffs and expands partnership with everwave
moreGrünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
Aachen, Germany & Yeoju, South Korea (ots) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will ...
moreGrünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands
Aachen, Germany (ots) - - Grünenthal acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. - Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 ...
more
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect
Aachen, Germany & Victoria, Australia (ots) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a ...
moreGrünenthal’s proprietary NaV 1.8 inhibitor enters clinical development
Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
moreFEV analysis: TCO cut by up to 33 percent through range extender trucks
moreGrünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex
Aachen, Germany & Toronto, Canada (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to ...
moreDaimler Buses teams up with FEV to launch the first hydrogen-powered Setra demonstrator vehicle
moreHenkel kicks off its anniversary year 2026
more
Fraunhofer-Institut für Produktionstechnologie IPT
3The future of 5G and 6G technology in industry: Completion of the EU project “TARGET-X”
moreFEV expands portfolio with advanced robotics and bundles expertise for sustainable and economical applications
moreFraunhofer-Institut für Produktionstechnologie IPT
More power in a smaller space: Compact press system for manufacturing hydrogen components
moreFEV and Nature Architects collaborate on the development of AI-supported, innovative vehicle structures
moreFEV and Chiyoda combine expertise for sustainable energy solutions
more- 5
PM: Ein elektrisches Jahrhundert: Wie sich Post-Fahrzeuge in Deutschland weiterentwickelt haben / PR: An electric century: The evolution of postal vehicles in Germany
more
Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors
Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...
moreGenerative AI accelerates homologation: FEV simplifies country-specific type approval processes
moreFraunhofer-Institut für Produktionstechnologie IPT
Transforming personalized medicine with AI-driven CAR-T manufacturing: Automated CAR-T cell production platform is ready for production
moreGrünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...
moreMaren Thurow starts as new Head Global Communications at Grünenthal
more- 2
urbanOS: The World's First Operating System for Smart Cities
more
- 2
Press Release - hubergroup takes BOPE films to a new level with the new Gecko 2-Component Varnish
One documentmore Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
more- 3
High-temperature heat pump for Südzucker subsidiary Tiense Suiker
more FEV develops AI-supported driver monitoring system CogniSafe
moreGrünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
moreFEV and ProLogium develop high-performance vehicle battery
more
12Next